DD251791A5 - Verfahren zur Herstellung von protease-resistenter Urokrinase - Google Patents

Verfahren zur Herstellung von protease-resistenter Urokrinase Download PDF

Info

Publication number: DD251791A5
Authority: DD; German Democratic Republic
Prior art keywords: urokinase; chain; item; human; lys
Prior art date: 1985-04-22

Application number

DD28944286A

Other languages

German (de)

English (en)

Inventor

Michael Blaber

Herbert L Heyneker

Gordon A Vehar

Original Assignee

Genentech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-04-22

Filing date

1986-04-21

Publication date

1987-11-25

1986-04-21 Application filed by Genentech Inc filed Critical Genentech Inc

1987-11-25 Publication of DD251791A5 publication Critical patent/DD251791A5/de

Links

108091005804 Peptidases Proteins 0.000 title claims abstract description 40
239000004365 Protease Substances 0.000 title claims abstract description 40
238000000034 method Methods 0.000 title claims description 39
230000008569 process Effects 0.000 title claims description 3
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 title abstract 3
238000004519 manufacturing process Methods 0.000 title description 4
108090000435 Urokinase-type plasminogen activator Proteins 0.000 claims abstract description 179
102000003990 Urokinase-type plasminogen activator Human genes 0.000 claims abstract description 179
229960005356 urokinase Drugs 0.000 claims abstract description 178
102000035195 Peptidases Human genes 0.000 claims abstract description 37
125000003275 alpha amino acid group Chemical group 0.000 claims abstract description 20
238000012217 deletion Methods 0.000 claims abstract description 15
230000037430 deletion Effects 0.000 claims abstract description 15
108020004707 nucleic acids Proteins 0.000 claims abstract description 7
102000039446 nucleic acids Human genes 0.000 claims abstract description 7
150000007523 nucleic acids Chemical class 0.000 claims abstract description 7
230000001131 transforming effect Effects 0.000 claims abstract description 4
238000006243 chemical reaction Methods 0.000 claims description 19
108090000623 proteins and genes Proteins 0.000 claims description 11
230000035772 mutation Effects 0.000 claims description 9
229940012957 plasmin Drugs 0.000 claims description 9
108090000790 Enzymes Proteins 0.000 claims description 8
102000004190 Enzymes Human genes 0.000 claims description 8
229940088598 enzyme Drugs 0.000 claims description 8
239000000203 mixture Substances 0.000 claims description 8
230000002797 proteolythic effect Effects 0.000 claims description 8
230000009466 transformation Effects 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 6
102000004169 proteins and genes Human genes 0.000 claims description 6
230000006337 proteolytic cleavage Effects 0.000 claims description 6
150000001875 compounds Chemical class 0.000 claims description 5
229910052588 hydroxylapatite Inorganic materials 0.000 claims description 4
238000011534 incubation Methods 0.000 claims description 4
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 claims description 4
NWUYHJFMYQTDRP-UHFFFAOYSA-N 1,2-bis(ethenyl)benzene;1-ethenyl-2-ethylbenzene;styrene Chemical compound C=CC1=CC=CC=C1.CCC1=CC=CC=C1C=C.C=CC1=CC=CC=C1C=C NWUYHJFMYQTDRP-UHFFFAOYSA-N 0.000 claims description 2
OCYROESYHWUPBP-CIUDSAMLSA-N Pro-Ile Chemical compound CC[C@H](C)[C@@H](C([O-])=O)NC(=O)[C@@H]1CCC[NH2+]1 OCYROESYHWUPBP-CIUDSAMLSA-N 0.000 claims description 2
230000001580 bacterial effect Effects 0.000 claims description 2
PXXJHWLDUBFPOL-UHFFFAOYSA-N benzamidine Chemical compound NC(=N)C1=CC=CC=C1 PXXJHWLDUBFPOL-UHFFFAOYSA-N 0.000 claims description 2
108010015796 prolylisoleucine Proteins 0.000 claims description 2
229920002684 Sepharose Polymers 0.000 claims 1
239000003729 cation exchange resin Substances 0.000 claims 1
238000003306 harvesting Methods 0.000 claims 1
230000003381 solubilizing effect Effects 0.000 claims 1
230000017854 proteolysis Effects 0.000 abstract description 14
230000015572 biosynthetic process Effects 0.000 abstract description 8
238000003780 insertion Methods 0.000 abstract description 8
230000037431 insertion Effects 0.000 abstract description 8
239000003795 chemical substances by application Substances 0.000 abstract description 7
230000004048 modification Effects 0.000 abstract description 5
238000012986 modification Methods 0.000 abstract description 5
238000003786 synthesis reaction Methods 0.000 abstract description 5
125000000539 amino acid group Chemical group 0.000 abstract description 3
239000003153 chemical reaction reagent Substances 0.000 abstract description 3
239000008139 complexing agent Substances 0.000 abstract description 3
238000012258 culturing Methods 0.000 abstract 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 23
108020004414 DNA Proteins 0.000 description 22
241000588724 Escherichia coli Species 0.000 description 20
210000004027 cell Anatomy 0.000 description 19
230000000694 effects Effects 0.000 description 19
239000012634 fragment Substances 0.000 description 19
239000013612 plasmid Substances 0.000 description 14
102000013566 Plasminogen Human genes 0.000 description 13
108010051456 Plasminogen Proteins 0.000 description 13
102000009123 Fibrin Human genes 0.000 description 11
108010073385 Fibrin Proteins 0.000 description 11
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 11
229950003499 fibrin Drugs 0.000 description 11
239000004098 Tetracycline Substances 0.000 description 10
229960002180 tetracycline Drugs 0.000 description 10
229930101283 tetracycline Natural products 0.000 description 10
235000019364 tetracycline Nutrition 0.000 description 10
150000003522 tetracyclines Chemical class 0.000 description 10
108091034117 Oligonucleotide Proteins 0.000 description 9
239000013598 vector Substances 0.000 description 9
239000003112 inhibitor Substances 0.000 description 8
108010073863 saruplase Proteins 0.000 description 8
108010088842 Fibrinolysin Proteins 0.000 description 7
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
238000001727 in vivo Methods 0.000 description 6
239000006166 lysate Substances 0.000 description 6
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 6
229920000053 polysorbate 80 Polymers 0.000 description 6
239000001488 sodium phosphate Substances 0.000 description 6
229910000162 sodium phosphate Inorganic materials 0.000 description 6
RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 6
239000004475 Arginine Substances 0.000 description 5
102000004594 DNA Polymerase I Human genes 0.000 description 5
108010017826 DNA Polymerase I Proteins 0.000 description 5
102000010911 Enzyme Precursors Human genes 0.000 description 5
108010062466 Enzyme Precursors Proteins 0.000 description 5
108091028043 Nucleic acid sequence Proteins 0.000 description 5
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 5
238000000502 dialysis Methods 0.000 description 5
229960000789 guanidine hydrochloride Drugs 0.000 description 5
PJJJBBJSCAKJQF-UHFFFAOYSA-N guanidinium chloride Chemical compound [Cl-].NC(N)=[NH2+] PJJJBBJSCAKJQF-UHFFFAOYSA-N 0.000 description 5
230000007062 hydrolysis Effects 0.000 description 5
238000006460 hydrolysis reaction Methods 0.000 description 5
108091008146 restriction endonucleases Proteins 0.000 description 5
241000894007 species Species 0.000 description 5
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 4
239000007983 Tris buffer Substances 0.000 description 4
230000003213 activating effect Effects 0.000 description 4
239000000872 buffer Substances 0.000 description 4
238000003776 cleavage reaction Methods 0.000 description 4
238000007796 conventional method Methods 0.000 description 4
101150077341 fhuA gene Proteins 0.000 description 4
239000000047 product Substances 0.000 description 4
238000000746 purification Methods 0.000 description 4
230000007017 scission Effects 0.000 description 4
239000000243 solution Substances 0.000 description 4
238000006467 substitution reaction Methods 0.000 description 4
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
241000894006 Bacteria Species 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
239000004472 Lysine Substances 0.000 description 3
ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
208000007536 Thrombosis Diseases 0.000 description 3
108090000631 Trypsin Proteins 0.000 description 3
102000004142 Trypsin Human genes 0.000 description 3
230000004913 activation Effects 0.000 description 3
229940024606 amino acid Drugs 0.000 description 3
150000001413 amino acids Chemical class 0.000 description 3
238000003556 assay Methods 0.000 description 3
230000029087 digestion Effects 0.000 description 3
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
239000013613 expression plasmid Substances 0.000 description 3
239000013604 expression vector Substances 0.000 description 3
239000003527 fibrinolytic agent Substances 0.000 description 3
230000003480 fibrinolytic effect Effects 0.000 description 3
239000000499 gel Substances 0.000 description 3
208000015181 infectious disease Diseases 0.000 description 3
238000000926 separation method Methods 0.000 description 3
239000011780 sodium chloride Substances 0.000 description 3
239000000758 substrate Substances 0.000 description 3
239000006228 supernatant Substances 0.000 description 3
238000012360 testing method Methods 0.000 description 3
239000012588 trypsin Substances 0.000 description 3
241001515965 unidentified phage Species 0.000 description 3
210000002700 urine Anatomy 0.000 description 3
SXOUIMVOMIGLHO-AATRIKPKSA-N (E)-3-(indol-2-yl)acrylic acid Chemical compound C1=CC=C2NC(/C=C/C(=O)O)=CC2=C1 SXOUIMVOMIGLHO-AATRIKPKSA-N 0.000 description 2
229920001817 Agar Polymers 0.000 description 2
108010054576 Deoxyribonuclease EcoRI Proteins 0.000 description 2
241001302584 Escherichia coli str. K-12 substr. W3110 Species 0.000 description 2
241000701959 Escherichia virus Lambda Species 0.000 description 2
241001524679 Escherichia virus M13 Species 0.000 description 2
ZRALSGWEFCBTJO-UHFFFAOYSA-N Guanidine Chemical compound NC(N)=N ZRALSGWEFCBTJO-UHFFFAOYSA-N 0.000 description 2
102000003960 Ligases Human genes 0.000 description 2
108090000364 Ligases Proteins 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
239000000020 Nitrocellulose Substances 0.000 description 2
229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
239000008272 agar Substances 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
238000010276 construction Methods 0.000 description 2
239000012530 fluid Substances 0.000 description 2
238000001502 gel electrophoresis Methods 0.000 description 2
238000002523 gelfiltration Methods 0.000 description 2
230000003301 hydrolyzing effect Effects 0.000 description 2
PLVPPLCLBIEYEA-UHFFFAOYSA-N indoleacrylic acid Natural products C1=CC=C2C(C=CC(=O)O)=CNC2=C1 PLVPPLCLBIEYEA-UHFFFAOYSA-N 0.000 description 2
238000001802 infusion Methods 0.000 description 2
238000002703 mutagenesis Methods 0.000 description 2
231100000350 mutagenesis Toxicity 0.000 description 2
229920001220 nitrocellulos Polymers 0.000 description 2
239000002773 nucleotide Chemical group 0.000 description 2
125000003729 nucleotide group Chemical group 0.000 description 2
239000008188 pellet Substances 0.000 description 2
239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
230000002093 peripheral effect Effects 0.000 description 2
OJUGVDODNPJEEC-UHFFFAOYSA-N phenylglyoxal Chemical compound O=CC(=O)C1=CC=CC=C1 OJUGVDODNPJEEC-UHFFFAOYSA-N 0.000 description 2
238000012216 screening Methods 0.000 description 2
230000035945 sensitivity Effects 0.000 description 2
238000012163 sequencing technique Methods 0.000 description 2
230000002537 thrombolytic effect Effects 0.000 description 2
230000026683 transduction Effects 0.000 description 2
238000010361 transduction Methods 0.000 description 2
ALBODLTZUXKBGZ-JUUVMNCLSA-N (2s)-2-amino-3-phenylpropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CC1=CC=CC=C1 ALBODLTZUXKBGZ-JUUVMNCLSA-N 0.000 description 1
DGYWXYFLXYIOCP-KBPBESRZSA-N (2s)-n-[2-[[(2s)-5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]amino]-2-oxoethyl]-5-oxopyrrolidine-2-carboxamide Chemical compound N([C@@H](CCCN=C(N)N)C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)C(=O)CNC(=O)[C@@H]1CCC(=O)N1 DGYWXYFLXYIOCP-KBPBESRZSA-N 0.000 description 1
QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
JQPFYXFVUKHERX-UHFFFAOYSA-N 2-hydroxy-2-cyclohexen-1-one Natural products OC1=CCCCC1=O JQPFYXFVUKHERX-UHFFFAOYSA-N 0.000 description 1
108010007858 5-oxo-prolyl-glycyl-arginine-4-nitroanilide Proteins 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
108700028369 Alleles Proteins 0.000 description 1
108090000531 Amidohydrolases Proteins 0.000 description 1
102000004092 Amidohydrolases Human genes 0.000 description 1
108091003079 Bovine Serum Albumin Proteins 0.000 description 1
102000014914 Carrier Proteins Human genes 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
102000012410 DNA Ligases Human genes 0.000 description 1
108010061982 DNA Ligases Proteins 0.000 description 1
108010053770 Deoxyribonucleases Proteins 0.000 description 1
102000016911 Deoxyribonucleases Human genes 0.000 description 1
108010016626 Dipeptides Proteins 0.000 description 1
108010059378 Endopeptidases Proteins 0.000 description 1
102000005593 Endopeptidases Human genes 0.000 description 1
108090000371 Esterases Proteins 0.000 description 1
108010091443 Exopeptidases Proteins 0.000 description 1
102000018389 Exopeptidases Human genes 0.000 description 1
229920001917 Ficoll Polymers 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
108010024636 Glutathione Proteins 0.000 description 1
108010053070 Glutathione Disulfide Proteins 0.000 description 1
244000068988 Glycine max Species 0.000 description 1
235000010469 Glycine max Nutrition 0.000 description 1
108091027305 Heteroduplex Proteins 0.000 description 1
241000282412 Homo Species 0.000 description 1
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 1
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 1
FADYJNXDPBKVCA-UHFFFAOYSA-N L-Phenylalanyl-L-lysin Natural products NCCCCC(C(O)=O)NC(=O)C(N)CC1=CC=CC=C1 FADYJNXDPBKVCA-UHFFFAOYSA-N 0.000 description 1
ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
239000006142 Luria-Bertani Agar Substances 0.000 description 1
102000016943 Muramidase Human genes 0.000 description 1
108010014251 Muramidase Proteins 0.000 description 1
241000699670 Mus sp. Species 0.000 description 1
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
CHJJGSNFBQVOTG-UHFFFAOYSA-N N-methyl-guanidine Natural products CNC(N)=N CHJJGSNFBQVOTG-UHFFFAOYSA-N 0.000 description 1
241001135910 Phage M13mp18 Species 0.000 description 1
102000001938 Plasminogen Activators Human genes 0.000 description 1
108010001014 Plasminogen Activators Proteins 0.000 description 1
108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
108010083644 Ribonucleases Proteins 0.000 description 1
102000006382 Ribonucleases Human genes 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
239000012506 Sephacryl® Substances 0.000 description 1
238000012300 Sequence Analysis Methods 0.000 description 1
108010022999 Serine Proteases Proteins 0.000 description 1
102000012479 Serine Proteases Human genes 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
108090000190 Thrombin Proteins 0.000 description 1
229940122618 Trypsin inhibitor Drugs 0.000 description 1
101710162629 Trypsin inhibitor Proteins 0.000 description 1
QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
PDSLRCZINIDLMU-QWRGUYRKSA-N Tyr-Glu Chemical compound OC(=O)CC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 PDSLRCZINIDLMU-QWRGUYRKSA-N 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
230000009471 action Effects 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
230000000274 adsorptive effect Effects 0.000 description 1
230000002411 adverse Effects 0.000 description 1
102000003801 alpha-2-Antiplasmin Human genes 0.000 description 1
108090000183 alpha-2-Antiplasmin Proteins 0.000 description 1
230000003024 amidolytic effect Effects 0.000 description 1
230000000636 anti-proteolytic effect Effects 0.000 description 1
230000000890 antigenic effect Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
210000001367 artery Anatomy 0.000 description 1
230000008901 benefit Effects 0.000 description 1
230000008275 binding mechanism Effects 0.000 description 1
108091008324 binding proteins Proteins 0.000 description 1
229940098773 bovine serum albumin Drugs 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000015556 catabolic process Effects 0.000 description 1
210000002421 cell wall Anatomy 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
239000003593 chromogenic compound Substances 0.000 description 1
238000004140 cleaning Methods 0.000 description 1
230000006957 competitive inhibition Effects 0.000 description 1
239000002299 complementary DNA Substances 0.000 description 1
OILAIQUEIWYQPH-UHFFFAOYSA-N cyclohexane-1,2-dione Chemical compound O=C1CCCCC1=O OILAIQUEIWYQPH-UHFFFAOYSA-N 0.000 description 1
SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
238000006731 degradation reaction Methods 0.000 description 1
230000000593 degrading effect Effects 0.000 description 1
239000003398 denaturant Substances 0.000 description 1
239000008121 dextrose Substances 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
SWSQBOPZIKWTGO-UHFFFAOYSA-N dimethylaminoamidine Natural products CN(C)C(N)=N SWSQBOPZIKWTGO-UHFFFAOYSA-N 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
238000001035 drying Methods 0.000 description 1
238000001962 electrophoresis Methods 0.000 description 1
238000010828 elution Methods 0.000 description 1
210000003038 endothelium Anatomy 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
238000009585 enzyme analysis Methods 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
230000020764 fibrinolysis Effects 0.000 description 1
230000004927 fusion Effects 0.000 description 1
RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 1
YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 1
229960004198 guanidine Drugs 0.000 description 1
230000023597 hemostasis Effects 0.000 description 1
230000002439 hemostatic effect Effects 0.000 description 1
238000000265 homogenisation Methods 0.000 description 1
229940106780 human fibrinogen Drugs 0.000 description 1
210000004408 hybridoma Anatomy 0.000 description 1
230000003053 immunization Effects 0.000 description 1
238000002649 immunization Methods 0.000 description 1
238000003018 immunoassay Methods 0.000 description 1
230000002163 immunogen Effects 0.000 description 1
230000006698 induction Effects 0.000 description 1
239000002198 insoluble material Substances 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
239000003456 ion exchange resin Substances 0.000 description 1
229920003303 ion-exchange polymer Polymers 0.000 description 1
229960000310 isoleucine Drugs 0.000 description 1
AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
238000005304 joining Methods 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
229960000274 lysozyme Drugs 0.000 description 1
239000004325 lysozyme Substances 0.000 description 1
235000010335 lysozyme Nutrition 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
239000011159 matrix material Substances 0.000 description 1
239000002609 medium Substances 0.000 description 1
108020004999 messenger RNA Proteins 0.000 description 1
244000005700 microbiome Species 0.000 description 1
239000006151 minimal media Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
230000000869 mutational effect Effects 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
230000001151 other effect Effects 0.000 description 1
YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
230000036961 partial effect Effects 0.000 description 1
230000010412 perfusion Effects 0.000 description 1
230000002688 persistence Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
230000033885 plasminogen activation Effects 0.000 description 1
229940127126 plasminogen activator Drugs 0.000 description 1
238000007747 plating Methods 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000002243 precursor Substances 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
108090000765 processed proteins & peptides Proteins 0.000 description 1
239000000700 radioactive tracer Substances 0.000 description 1
239000011541 reaction mixture Substances 0.000 description 1
230000008707 rearrangement Effects 0.000 description 1
238000010188 recombinant method Methods 0.000 description 1
238000011084 recovery Methods 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
150000003839 salts Chemical class 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
230000003248 secreting effect Effects 0.000 description 1
238000007086 side reaction Methods 0.000 description 1
238000002741 site-directed mutagenesis Methods 0.000 description 1
239000002002 slurry Substances 0.000 description 1
FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
229940048086 sodium pyrophosphate Drugs 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
238000010998 test method Methods 0.000 description 1
235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
229960004072 thrombin Drugs 0.000 description 1
229960000103 thrombolytic agent Drugs 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000002463 transducing effect Effects 0.000 description 1
239000002753 trypsin inhibitor Substances 0.000 description 1
210000005166 vasculature Anatomy 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
238000005406 washing Methods 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000001262 western blot Methods 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
- C12N15/102—Mutagenizing nucleic acids
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/67—General methods for enhancing the expression
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
- C12N15/71—Expression systems using regulatory sequences derived from the trp-operon
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6456—Plasminogen activators
- C12N9/6459—Plasminogen activators t-plasminogen activator (3.4.21.68), i.e. tPA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21069—Protein C activated (3.4.21.69)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Life Sciences & Earth Sciences (AREA)
Engineering & Computer Science (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biomedical Technology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Molecular Biology (AREA)
Plant Pathology (AREA)
Biophysics (AREA)
Physics & Mathematics (AREA)
Medicinal Chemistry (AREA)
Crystallography & Structural Chemistry (AREA)
Enzymes And Modification Thereof (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

DD28944286A 1985-04-22 1986-04-21 Verfahren zur Herstellung von protease-resistenter Urokrinase DD251791A5 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US72546885A	1985-04-22	1985-04-22
US06/766,858 US5219569A (en)	1985-04-22	1985-08-16	Protease resistant urokinase

Publications (1)

Publication Number	Publication Date
DD251791A5 true DD251791A5 (de)	1987-11-25

Family

ID=27111148

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DD28944286A DD251791A5 (de)	1985-04-22	1986-04-21	Verfahren zur Herstellung von protease-resistenter Urokrinase
DD31055486A DD264939A5 (de)	1985-04-22	1986-04-21	Verfahren zur Herstellung einer Nucleinsäure

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
DD31055486A DD264939A5 (de)	1985-04-22	1986-04-21	Verfahren zur Herstellung einer Nucleinsäure

Country Status (10)

Country	Link
US (1)	US5219569A (fr)
EP (1)	EP0200451B1 (fr)
AT (1)	ATE98686T1 (fr)
DD (2)	DD251791A5 (fr)
DE (1)	DE3689386T2 (fr)
DK (1)	DK175304B1 (fr)
ES (1)	ES8800347A1 (fr)
GR (1)	GR861036B (fr)
HU (1)	HU202586B (fr)
PT (1)	PT82428B (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5204255A (en) *	1986-01-31	1993-04-20	Sagami Chemical Research Center	Hybrid tissue plasminogen activator/urokinase polypeptides
EP0236040A3 (fr) *	1986-02-26	1989-05-03	Collaborative Research Inc.	Prourokinase modifiée dans des acides aminés, et méthode de préparation
JPH0761266B2 (ja) *	1986-07-03	1995-07-05	株式会社ミドリ十字	変異ヒトプロウロキナ−ゼ
WO1988005081A2 (fr) *	1986-12-30	1988-07-14	Cetus Corporation	Nouveaux activateurs du plasminogene
US5009888A (en) *	1987-04-13	1991-04-23	Genzyme Corporation	Therapeutic enzyme-antibody complexes
MY103358A (en) *	1987-04-15	1993-06-30	Novartis Ag	Process for the production of protiens.
EP0330700B1 (fr) *	1987-08-19	1993-12-22	Sagami Chemical Research Center	Polypeptide ressemblant à la prourokinase humaine
US5591603A (en) *	1987-08-28	1997-01-07	Novo Nordisk A/S	Process for preparing aprotinin and aprotinin analogs in yeast cells
DK450187D0 (da) *	1987-08-28	1987-08-28	Novo Industri As	Fremgangsmaade til fremstilling af proteiner
DE3735917A1 (de) *	1987-10-23	1989-05-03	Basf Ag	Neue polypeptide, ihre herstellung und verwendung
DE3735916A1 (de) *	1987-10-23	1989-05-03	Basf Ag	Neue polypeptide, ihre herstellung und verwendung
JPH0322979A (ja) *	1989-06-19	1991-01-31	Kyowa Hakko Kogyo Co Ltd	新規プラスミノーゲン活性化因子
US5658871A (en) *	1989-07-07	1997-08-19	Lever Brothers Company, Division Of Conopco, Inc.	Microbial lipase muteins and detergent compositions comprising same
GB8915658D0 (en) *	1989-07-07	1989-08-23	Unilever Plc	Enzymes,their production and use
US5240845A (en) *	1989-07-11	1993-08-31	Otsuka Pharmaceutical Factory, Ltd.	Mutated streptokinase proteins
US5087572A (en) *	1989-12-01	1992-02-11	Genentech, Inc.	Dna encoding human plasminogen modified at the cleavage site
WO1994028145A2 (fr)	1993-06-01	1994-12-08	Chiron Corporation	Expression d'inhibiteurs de l'activateur de l'urokinase-plasminogene
US6248715B1 (en)	1993-06-01	2001-06-19	Chiron Corporation	Method of treating a urokinase-type plasminogen activator-mediated disorder
ATE226642T1 (de) *	1994-07-07	2002-11-15	Tno	Modifizierte proenzyme als substrate für proteolische enzyme
AU2091397A (en) *	1996-03-12	1997-10-01	Novo Nordisk A/S	Novel achromobacter lyticus protease variants
CN1311076C (zh) *	2003-04-16	2007-04-18	普罗特奥姆技术公司	生产重组尿激酶的方法
US7361493B1 (en)	2004-05-26	2008-04-22	The United States Of America As Represented By The Secretary Of The Department Of Veterans Affairs	Production of urokinase in a three-dimensional cell culture
GB2446550B (en) *	2005-11-28	2010-12-08	Proteomtech Inc	Methods for production of recombinant alpha1-antitrypsin
US20160146834A1 (en)	2013-07-12	2016-05-26	Emory University	Diagnostic assay to predict cardiovascular risk
US9783587B1 (en)	2014-05-09	2017-10-10	Florida State University Research Foundation	Synthetic foldable proteins generated from peptide segments of folding nuclei of reference proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4381346A (en) *	1979-11-13	1983-04-26	Huasin Syed S	Isolation of plasminogen activators useful as therapeutic and diagnostic agents
US4370417A (en) *	1980-04-03	1983-01-25	Abbott Laboratories	Recombinant deoxyribonucleic acid which codes for plasminogen activator
GR78180B (fr) *	1982-04-15	1984-09-26	Genentech Inc
EP0210279B1 (fr) *	1985-01-25	1991-08-14	Sagami Chemical Research Center	Prourokinase humaine stabilisee
EP0236040A3 (fr) *	1986-02-26	1989-05-03	Collaborative Research Inc.	Prourokinase modifiée dans des acides aminés, et méthode de préparation

1985
- 1985-08-16 US US06/766,858 patent/US5219569A/en not_active Expired - Lifetime
1986
- 1986-04-21 DE DE3689386T patent/DE3689386T2/de not_active Expired - Lifetime
- 1986-04-21 EP EP86302981A patent/EP0200451B1/fr not_active Expired - Lifetime
- 1986-04-21 DK DK198601813A patent/DK175304B1/da not_active IP Right Cessation
- 1986-04-21 PT PT82428A patent/PT82428B/pt unknown
- 1986-04-21 GR GR861036A patent/GR861036B/el unknown
- 1986-04-21 DD DD28944286A patent/DD251791A5/de unknown
- 1986-04-21 DD DD31055486A patent/DD264939A5/de unknown
- 1986-04-21 HU HU861656A patent/HU202586B/hu unknown
- 1986-04-21 AT AT86302981T patent/ATE98686T1/de not_active IP Right Cessation
- 1986-04-22 ES ES554249A patent/ES8800347A1/es not_active Expired

Also Published As

Publication number	Publication date
GR861036B (en)	1986-07-16
ATE98686T1 (de)	1994-01-15
DK175304B1 (da)	2004-08-16
EP0200451B1 (fr)	1993-12-15
DD264939A5 (de)	1989-02-15
ES8800347A1 (es)	1987-11-16
DK181386A (da)	1986-10-23
DE3689386D1 (de)	1994-01-27
DK181386D0 (da)	1986-04-21
ES554249A0 (es)	1987-11-16
US5219569A (en)	1993-06-15
PT82428B (pt)	1988-03-03
HU202586B (en)	1991-03-28
HUT40696A (en)	1987-01-28
PT82428A (en)	1986-05-01
EP0200451A1 (fr)	1986-11-05
DE3689386T2 (de)	1994-05-19

Legal Events

Date	Code	Title	Description
2004-04-28	IF04	In force in the year 2004	Expiry date: 20060422

Publication	Publication Date	Title
DE3689386T2 (de)	1994-05-19	Proteaseresistente Urokinase-Zusammensetzung, deren Herstellung und Verwendung.
DE3382760T2 (de)	1995-03-02	Herstellung von funktionellen menschlichen Urokinasepolypeptiden.
DE3613390C2 (de)	2001-10-11	Einkettige Human-Gewebeplasminogen-Aktivator (t-PA)-Mutanten, kodierende DNA, Expressionsvektor, Mikroorganismus, Zellkultur und pharmazeutische Zusammensetzung
CA2025900C (fr)	1999-01-19	Derive d'un activateur du plasminogene de type tissulaire
JP2631645B2 (ja)	1997-07-16	新規化合物、その製法及びそれを含む医薬組成物
DE68923741T2 (de)	1996-02-15	Fledermausspeichel-Plasminogenaktivatoren.
DE68916532T2 (de)	1995-01-12	Varianten von menschlichem gewebeplasminogenaktivator sowie verfahren zu deren herstellung.
JPS6291187A (ja)	1987-04-25	ヒト組織プラスミノーゲン活性化因子をコードしているｄｎａを発現し得る組換え発現ベクターで形質転換された宿主細胞
DE69009068T2 (de)	1994-10-27	Methoden und materialien zur expression von varianten von menschlichem plasminogen.
US5747291A (en)	1998-05-05	Bifunctional urokinase variants with improved fibrinolytic characteristics and thrombin inhibiting effect
DE69321134T2 (de)	1999-02-25	Plasminogen-derivate die durch thrombin aktivierbar sind
EP0714982A2 (fr)	1996-06-05	Protéines hybrides, ayant des propriétés fibrinolytiques et inhibant la thrombine
DE4423574A1 (de)	1996-01-11	Nicht-glykosylierte Plasminogenaktivator-Derivate und ihre Verwendung bei erhöhtem Blutungsrisiko
EP0712934A2 (fr)	1996-05-22	Protéines avec une activité fibrinolytique et anticoagulante
EP0400545B1 (fr)	1995-03-15	Dérivé de l'activateur tissulaire du plasminogène
JP2000504941A (ja)	2000-04-25	トロンビンによって活性化され得るプラスミノーゲンアクチベーター
EP0819173B1 (fr)	2004-05-06	Mutant de l'inhibiteur du type erythrina caffra et son utilisation pour la purification des serine-proteases
IE861054L (en)	1986-10-22	Protease resistant single-chain urokinase
DE4443273A1 (de)	1996-06-13	Verwendung der Proteasedomäne von humanem Plasminogenaktivator zur Behandlung von thromboembolischen Erkrankungen
WO1999009184A1 (fr)	1999-02-25	Activateur du plasminogene a pouvoir zymogene ameliore et a liaison a la fibrine reduite
WO1999009185A1 (fr)	1999-02-25	Activateur du plasminogene avec zymogenite amelioree
JPH0739374A (ja)	1995-02-10	新規なｔ−ＰＡ改変体
JPH01160481A (ja)	1989-06-23	新規なポリペプチド、その製法及び用途
DD231372A5 (de)	1985-12-24	Herstellung funktioneller menschlicher urokinaseproteine
HK1010111A (en)	1999-06-11	Chimera proteins with fibrinolytic and coagulation inhibiting characteristics